AVASTIN Drug Insight

“AVASTIN Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about AVASTIN for glioblastoma multiforme (GBM) and ovarian cancer in the seven major markets. A detailed picture of the AVASTIN in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the AVASTIN. The report provides insights about the mechanism of action, dosage, and administration, as well as research and development, including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the AVASTIN market forecast analysis in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies.

Drug Summary

AVASTIN (bevacizumab) is a recombinant humanized monoclonal IgG1 antibody, which acts as an angiogenesis inhibitor by blocking its target, vascular endothelial growth factor (VEGF). Bevacizumab binds to the VEGF with its receptors VEGFR-1 and VEGFR-2, which are present on the surface of endothelial cells. This helps reduce VEGF activity and regress the vascularization of tumors, normalizing the tumor vasculature and inhibiting the formation of new tumor vasculature, thereby preventing tumor growth. VEGF is a chemical signal that stimulates angiogenesis in various diseases, especially cancer. Bevacizumab is the first clinically available angiogenesis inhibitor in the United States. In September 2014, Genentech reclassified the drug under “Specialty drugs,” only to be available through specialty pharmacies (under FDA’s risk evaluation and mitigation strategy [REMS] program) (Genentech, n.d.). AVASTIN is indicated for treating GBM with progressive disease in adult patients following prior therapy as a single agent. The effectiveness of AVASTIN in GBM is based on an improvement in objective response rate. No available data demonstrate any improvement in disease-related symptoms or increased survival with AVASTIN in GBM.

Dosage: 10 mg/kg IV every 2 weeks.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the AVASTIN description, mechanism of action, dosage and administration, research and development activities in glioblastoma multiforme (GBM) and ovarian cancer.
• Elaborated details on AVASTIN regulatory milestones and other development activities have been provided in this report.
• The report also highlights the AVASTIN research and development activities in glioblastoma multiforme (GBM) and ovarian cancer across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around AVASTIN.
• The report contains forecasted sales of AVASTIN for glioblastoma multiforme (GBM) and ovarian cancer until 2032.
• Comprehensive coverage of the late-stage emerging therapies for glioblastoma multiforme (GBM) and ovarian cancer.
• The report also features the SWOT analysis with analyst views for AVASTIN in glioblastoma multiforme (GBM) and ovarian cancer.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities' websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals, and access to available databases.

AVASTIN Analytical Perspective by DelveInsight

• In-depth AVASTIN Market Assessment

This report provides a detailed market assessment of AVASTIN for glioblastoma multiforme (GBM) and ovarian cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

• AVASTIN Clinical Assessment

The report provides the clinical trials information of AVASTIN for glioblastoma multiforme (GBM) and ovarian cancer, covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for glioblastoma multiforme (GBM) and ovarian cancer is set to change due to the extensive research and incremental healthcare spending across the world, which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• Companies are developing therapies that focus on novel approaches to treat/improve disease conditions, assess challenges, and seek opportunities that could influence AVASTIN dominance.
• Other emerging products for GBM are expected to give tough market competition to AVASTIN, and the launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones and developmental activities provides the current development scenario of AVASTIN in GBM.
• Our in-depth analysis of the forecasted sales data of AVASTIN from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of AVASTIN in GBM.

Key Questions

• What is the product type, route of administration, and mechanism of action of AVASTIN?
• What is the clinical trial status of the study related to AVASTIN in glioblastoma multiforme (GBM) and ovarian cancer, and the study completion date?
• What are the key collaborations, mergers, acquisitions, licensing, and other activities related to the AVASTIN development?
• What are the key designations that have been granted to AVASTIN for glioblastoma multiforme (GBM) and ovarian cancer?
• What is the forecasted market scenario of AVASTIN for glioblastoma multiforme (GBM) and ovarian cancer?
• What are the forecasted sales of AVASTIN in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available, and how are these competing with AVASTIN for glioblastoma multiforme (GBM) and ovarian cancer?
• Which are the late-stage emerging therapies under development for the treatment of glioblastoma multiforme (GBM) and ovarian cancer?